Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Efstathiou

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
Urologic Oncology|January 7, 2023
Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapyCarlos Riveros, Sanjana Ranganathan, Jiaqiong Xu, et al.
European Urology|June 10, 2019
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus PrednisoneEleni Efstathiou, John W Davis, Louis Pisters, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
The Lancet. Oncology|August 1, 2014
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric OncologyJean-Pierre Droz, Matti Aapro, Lodovico Balducci, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5Karim Fizazi, Robert Jones, Stephane Oudard, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Urologic Oncology|January 7, 2023
Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapyCarlos Riveros, Sanjana Ranganathan, Jiaqiong Xu, et al.
European Urology|June 10, 2019
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus PrednisoneEleni Efstathiou, John W Davis, Louis Pisters, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
The Lancet. Oncology|August 1, 2014
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric OncologyJean-Pierre Droz, Matti Aapro, Lodovico Balducci, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5Karim Fizazi, Robert Jones, Stephane Oudard, et al.
Pageof 15